Therapeutics and Biomaterials for Musculoskeletal Disease: Global Markets

Jul 2010| HLC086A| BCC Publishing

Report Highlights

  • The global market for musculoskeletal disease is currently approaching $45 billion.  The overall 5-year compound annual growth rate (CAGR) is forecasted to be about 5%, bringing the total market to more than $57 billion by 2014.
  • Rheumatoid arthritis and osteoarthritis currently represent 53% of the total market.  The RA market was worth an estimated $9.5 billion in 2009 and should reach nearly $12.5 billion by 2015, while the osteoarthritis segment was valued at $14.5 billion in 2009 and should reach an estimated $19 billion by 2014. For both sectors this represents a compound annual growth rate (CAGR) of 5.6%.
  • Lupus is an emerging area for development, as outcome measures and understanding of the disease pathology become more refined. This segment was valued at $1.5 billion in 2009 and is projected to reach $2 billion by 2014, a compound annual growth rate (CAGR) of 5.2%.


BCC’s goal in conducting this study was to determine the current status of the musculoskeletal disease (MSD) treatments and assess the growth potential of this area over a 5-year period from 2009 to 2014. 
Our key objective was to present a comprehensive analysis of the current pipeline of therapeutics and biomaterials utilized in the treatment of MSDs, analyze the market and forecast for MSD therapeutics and treatments, and outline the key factors that will influence this therapeutic area in the next few years. 
Diseases of the musculoskeletal system have plagued a significant portion of the population, and the number of incidence increases as the population ages. There have been many successful therapeutics marketed to date, but there is still room for more effective therapies. Advances in biomaterials are being translated into viable products in the orthobiologics area as well, thus changing the way a number of related disease states are treated. More is being elucidated about these diseases, and this promises to translate into more therapies and market opportunities for a variety of players.
Musculoskeletal disease affects roughly 20% of the population and is a significant factor in overall healthcare expenditure. Diseases such as rheumatoid arthritis, osteoporosis, and osteoarthritis are treated with various drug types, and a large development pipeline of potential new therapies is currently being tested. Clinical success has proven elusive, however, as there are now numerous companies developing novel treatments. This report reviews the programs in development and quantifies the market opportunities in MSDs. This study aims to quantify the direction in which this market is heading and the areas in which opportunities may lie.
The scope of this report focuses on the ethical pharmaceutical segment and biomaterials areas, usually categorized with medical devices. We have compiled a study of the market, as well as current and emerging modes of treatment. We present the segment economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for the time period from 2009 to 2014. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients, and the medical community. It will also be of interest also to suppliers of products and services to this market area.
The intended audience for this report is the pharmaceutical and biotechnology diagnostics industries, as well as the medical industry that treats patients in these areas.
BCC presents an analysis by each disease area and the number of current patients. Based on our surveys, we then analyze the potential applications for pharmaceuticals and forecast markets for 2009 and 2014. 
BCC surveyed approximately 50 companies to obtain data for this study. Included were drug development and device companies and medical professionals. We also spoke with patients affected by musculoskeletal diseases. In addition, we compiled data from current financial and trade information and government sources.
Maura Lane Warner has more than 18 years of experience primarily in the biotechnology and pharmaceutical industries as a business development and market development executive with additional experience in operations and portfolio management. 
Maura has worked at Wyeth/Genetics Institute and Shire Pharmaceuticals along with a number of venture-backed startup companies, successfully closing numerous licensing and partnership transactions and commercializing therapeutics and technology platforms.
She has a BS in Chemical Engineering and an MBA in Marketing and Finance. Maura has also authored previous reports titled Therapeutics and Diagnostics for Alzheimer’s Disease: Global Markets and Therapeutics for Memory and Cognition.
BCC offers an online information retrieval service. BCC’s home page, located at, enables readers to:
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Title/Chapter NamePagesPrice Member Price
Full Report: Therapeutics and Biomaterials for Musculoskeletal Disease: Global Markets214 $2,750 Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: SUMMARY3$250Free
Chapter- 3: OVERVIEW43$553Free
Chapter- 4: THERAPEUTICS45$578Free
Chapter- 7: PIPELINE7$90Free
Chapter- 8: PATENT ANALYSIS29$373Free
Chapter- 9: COMPANY PROFILES76$977Free
Market Research Report

Single User License: $2750

Member Price: FREE

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries